Fact sheet: FL AXA Framlington Health AP

Fund information
Fund name
FL AXA Framlington Health AP
Fund manager company
Friends Life
Fund type
Pension Fund
Fund managers
  • Dani Saurympersince 01/04/2015
Underlying fund
AXA Framlington Health
Fund objective
AXA state that the aim of the fund is to generate capital growth through investment in healthcare and medical services and product companies worldwide. Investment will be in producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies.
Benchmark
  • MSCI World Healthcare
Investment style
Growth
Investment method
No data available.
Quick stats
1 Year return
18.8%
1 Year rank in sector
180/536
Sector
PN Specialist
Yield
-
Fund size
£3m (£2m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
138
Top in this sector
Fund name1 Year
Scot Eq Technology Pn52.9%
SIP Sanlam Gbl Fin Pn50.6%
SIP Fidelity Gbl Technology Pn49.2%
OMW Neptune Rus + Grtr Rus48.3%
FL AXA Framlington Gbl Tech AP48.2%
...more in PN Specialist

Performance snapshot

Holdings snapshot

  • North America68.6%
    Europe ex UK14.8%
    UK10.1%
    Money Market3%
    Japan2.6%
  • Pharmaceuticals29.8%
    Biotechnology/Medical25.6%
    Health Care19.3%
    Healthcare & Medical Products17.8%
    Money Market3%
  • North American Equities68.6%
    Europe ex UK Equities14.8%
    UK Equities10.1%
    Money Market3%
    Japanese Equities2.6%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund-0.8%5.6%4.2%18.8%68.7%148.4%
Sector0.4%2.8%3.2%13.7%25.2%44.6%
Rank within sector517 / 55955 / 559152 / 551180 / 53615 / 3977 / 337
Quartile4th1st2nd2nd1st1st
Calendar performance
 YTD - 20172016201520142013
Fund6.1%8.6%13.3%31.3%36.3%
Sector3%11.6%2%7.2%11%
Rank within sector46 / 555283 / 5197 / 4548 / 3927 / 365
Quartile1st3rd1st1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
4.51
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.84
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
1.06
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
14.55
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
10.81
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.96
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.56
Price movement
52 week high559.3
52 week low429.4
Current bid price-
Current offer price-
Current mid price530.5
Region
1North America68.58%
2Europe ex UK14.8%
3UK10.08%
4Money Market2.98%
5Japan2.62%
6Global Emerging Markets0.94%
Industry sector
1Pharmaceuticals29.83%
2Biotechnology/Medical25.62%
3Health Care19.34%
4Healthcare & Medical Products17.76%
5Money Market2.98%
6Hospital1.86%
7Food & Drug Retailers1.38%
8Conglomerates1.23%
Asset type
1North American Equities68.58%
2Europe ex UK Equities14.8%
3UK Equities10.08%
4Money Market2.98%
5Japanese Equities2.62%
6Global Emerging Market Equities0.94%
Individual holdings
1ROCHE HLDG AG5.2%
2GLAXOSMITHKLINE4.9%
3UNITEDHEALTH GROUP INC4.6%
4ALLERGAN PLC4.5%
5CELGENE CORP4.2%
6GILEAD SCIENCES INC3.7%
7MEDTRONIC INC3.6%
8LILLY (ELI) & CO2.9%
9SHIRE PLC2.5%
Management
Fund manager group
Friends Life
Fund manager company
Friends Life
Fund type
Pension Fund
Fund objective
AXA state that the aim of the fund is to generate capital growth through investment in healthcare and medical services and product companies worldwide. Investment will be in producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies.
Benchmark
  • MSCI World Healthcare
Investment style
Growth
Investment method
No data available.
Fund managers
NameSinceBiography
Dani Saurymper01/04/2015Dani Saurymper joined AXA IM in April 2015 as Portfolio Manager for the AXA Framlington Health funds. Dani has 14 years’ experience. Prior to joining AXA IM in April 2015 as Portfolio Manager, he was a senior equity research analyst covering European Healthcare at Barclays Capital. Dani started his career at Goldman Sachs as a senior pharmaceutical analyst covering European Pharmaceuticals, before moving to Nomura as a sector specialist covering global healthcare Dani graduated from Leeds University with a BSc in Management Studies and Pharmacology and holds an MSc in International Business from the Manchester School of Management, UMIST.
Compliance
No data available.
Domicile
No data available.
Fund for sale in
United Kingdom
FL AXA Framlington Health AP
Initial charge-
Annual charge1.8%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.88%
Bid price-
Offer price-
Mid price530.5
CurrencyGBX
Price updated27/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGT32
FL AXA Framlington Health AP Acc Inet
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price315.1
Offer price331.7
Mid price-
CurrencyGBX
Price updated27/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeG767
FL AXA Framlington Health AP Inet
Initial charge-
Annual charge1.8%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.88%
Bid price-
Offer price-
Mid price1613.1
CurrencyGBX
Price updated27/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeG926
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.